Janssen

Website: janssen.com

Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology, immunology, neuroscience, infectious diseases, cardiovascular and metabolic diseases.

Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency.

Content provided by this sponsor:

Session from the ESMO 2014 Congress

A Janssen-sponsored satellite symposium entitled 'Navigating the evolving treatment landscape in metastatic CRPC' was included as part of the ESMO 2014 Congress in Madrid, Spain.

• Welcome and introduction
• Targeting the androgen axis in prostate cancer
• Selecting optimal first-line treatment for metastatic castration-resistant prostate cancer (CRPC)
• Panel discussion: When to start treatment in mCRPC
• Sequencing considerations
• Panel discussion: How does biology drive the appropriate sequencing of therapy?
• Interpreting clinical trial data for daily clinical practice
• Summary and close

The educational objectives were that at the end of the session participants should be able to:

• Discuss treatment options for patients with metastatic castration-resistant prostate cancer
• Identify strategies for the practical management of patients with advanced prostate cancer

In an era which has brought many advances in the treatment of metastatic castration-resistant prostate cancer there are new challenges in determining optimal first-line and subsequent therapies. Therefore, in this symposium, the co-chairs Joan Carles (Spain) and Cora Sternberg (Italy) together with Gert Attard (UK), Eleni Efstathiou (Greece) and Maria De Santis (Austria) discussed how a critical assessment of the available data can help ensure that only relevant developments are applied in daily clinical practice.

Presentation from the 2011 European Multidisciplinary Cancer Congress

• Evolving treatment options in castration-resistant prostate cancer

ESMO only accepts content from third parties after careful evaluation of its educational and scientific relevance to the ESMO target audience. Eligible material should meet the essential criterion of non-promotional intent. Such material may be published in other resources, but the content donor has given permission to ESMO for use in OncologyPRO.